Hepatitis B continues to drive major liver disease and cancer burden because chronic infection often stays undiagnosed and untreated. WHO estimates hepatitis B causes 1.5 million deaths each year from liver disease and cancer. In the United States, 70.3% of adults who met treatment eligibility criteria for chronic hepatitis B had not received it as of 2017.
Key Takeaways
- 10.0% of adults aged 30 years and older in China were hepatitis B surface antigen (HBsAg) positive in 2018
- 6.0% of adults aged 20 years and older in the United States were hepatitis B surface antigen (HBsAg) positive in 2015–2018
- WHO estimates hepatitis B causes 1.5 million deaths annually from liver disease and cancer (2019 global estimates)
- Chronic hepatitis B increases risk of cirrhosis, liver failure, and liver cancer without treatment
- Annual incidence of HCC in chronic hepatitis B varies substantially by risk group (e.g., higher in males and those with cirrhosis)
- Antiviral therapy reduces all-cause mortality in chronic hepatitis B patients
- 84% of infants worldwide received the hepatitis B vaccine birth dose in 2022
- Tenofovir disoproxil fumarate has demonstrated sustained viral suppression in chronic hepatitis B over multiple years of follow-up in clinical studies
- Entecavir is associated with high rates of durable virologic response in treatment-naive chronic hepatitis B patients
- 296,000 deaths were estimated to be attributable to hepatitis B in 2019 in the Global Burden of Disease study
- 70.3% of adults with chronic hepatitis B in the United States who met eligibility criteria for treatment had not received it as of 2017
- 8.2% seroprevalence of hepatitis B surface antigen (HBsAg) among the general population in China (overall pooled estimate, systematic review)
- Approximately 12% of people with chronic hepatitis B infection develop cirrhosis over their lifetime
- 1% of people with chronic hepatitis B infection develop hepatocellular carcinoma each year
- 20–25% of people with chronic hepatitis B who develop cirrhosis die from liver-related complications
Fewer infants and adults are diagnosed and treated, but vaccination and antivirals can prevent millions of deaths.
Related reading
01 · Category
Global Burden3 stats
01
10.0% of adults aged 30 years and older in China were hepatitis B surface antigen (HBsAg) positive in 2018
02
6.0% of adults aged 20 years and older in the United States were hepatitis B surface antigen (HBsAg) positive in 2015–2018
03
WHO estimates hepatitis B causes 1.5 million deaths annually from liver disease and cancer (2019 global estimates)
Interpretation
Global Burden Interpretation
From a global burden perspective, hepatitis B remains widespread with HBsAg positivity affecting 10.0% of adults 30 and older in China in 2018 and 6.0% of adults 20 and older in the United States in 2015 to 2018, while WHO estimates the resulting liver disease and cancer kill about 1.5 million people each year.
02 · Category
Outcomes & Risk3 stats
01
Chronic hepatitis B increases risk of cirrhosis, liver failure, and liver cancer without treatment
02
Annual incidence of HCC in chronic hepatitis B varies substantially by risk group (e.g., higher in males and those with cirrhosis)
03
Antiviral therapy reduces all-cause mortality in chronic hepatitis B patients
Interpretation
Outcomes & Risk Interpretation
Under the Outcomes & Risk category, chronic hepatitis B substantially raises the chances of severe liver outcomes such as cirrhosis, liver failure, and liver cancer without treatment, while annual HCC incidence varies widely by risk group and antiviral therapy is linked to reduced all-cause mortality in chronic hepatitis B patients.
03 · Category
Vaccination & Testing1 stats
01
84% of infants worldwide received the hepatitis B vaccine birth dose in 2022
Interpretation
Vaccination & Testing Interpretation
In the Vaccination and Testing category, 84% of infants worldwide got the hepatitis B birth dose in 2022, showing strong uptake of the key early vaccination step.
04 · Category
Diagnostics & Care2 stats
01
Tenofovir disoproxil fumarate has demonstrated sustained viral suppression in chronic hepatitis B over multiple years of follow-up in clinical studies
02
Entecavir is associated with high rates of durable virologic response in treatment-naive chronic hepatitis B patients
Interpretation
Diagnostics & Care Interpretation
In Diagnostics and Care, both tenofovir disoproxil fumarate and entecavir show strong long term disease control in chronic hepatitis B, with tenofovir sustaining viral suppression across multiple years and entecavir delivering high durable virologic response rates in treatment naive patients.
05 · Category
Epidemiology3 stats
01
296,000 deaths were estimated to be attributable to hepatitis B in 2019 in the Global Burden of Disease study
02
70.3% of adults with chronic hepatitis B in the United States who met eligibility criteria for treatment had not received it as of 2017
03
8.2% seroprevalence of hepatitis B surface antigen (HBsAg) among the general population in China (overall pooled estimate, systematic review)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, hepatitis B remains a major global burden with an estimated 296,000 deaths in 2019, while untreated disease is still widespread in the US where 70.3% of eligible adults had not received treatment by 2017, and infection exposure in large populations like China is reflected by an 8.2% HBsAg seroprevalence.
06 · Category
Disease Progression5 stats
01
Approximately 12% of people with chronic hepatitis B infection develop cirrhosis over their lifetime
02
1% of people with chronic hepatitis B infection develop hepatocellular carcinoma each year
03
20–25% of people with chronic hepatitis B who develop cirrhosis die from liver-related complications
04
Up to 30% of children infected with hepatitis B at birth develop chronic infection and are at higher risk of premature death over the life course
05
3.6% annual HBsAg seroclearance rate was reported in a long-term cohort study of untreated chronic hepatitis B patients
Interpretation
Disease Progression Interpretation
From a disease progression perspective, chronic hepatitis B leaves a notable lifelong risk with about 12% developing cirrhosis and roughly 1% progressing to hepatocellular carcinoma each year, while outcomes worsen further because 20 to 25% of those who reach cirrhosis die from liver-related complications.
07 · Category
Treatment Outcomes5 stats
01
45.9% of HBeAg-positive chronic hepatitis B patients achieved HBeAg seroconversion after 96 weeks of entecavir in a randomized trial
02
75% of HBeAg-positive patients receiving tenofovir disoproxil fumarate achieved virologic response (HBV DNA <400 copies/mL) by week 48 in a randomized trial
03
97% of treated chronic hepatitis B patients receiving tenofovir alafenamide achieved sustained virologic suppression through 3 years (HBV DNA below lower limit of quantification)
04
80% of patients with chronic hepatitis B treated with pegylated interferon achieved HBeAg seroconversion by week 48 in a meta-analysis of trials
05
2.6-fold higher risk of HCC was observed in chronic hepatitis B patients who remained HBsAg-positive after seroconversion to anti-HBs following treatment cessation in a cohort study
Interpretation
Treatment Outcomes Interpretation
Across major Treatment Outcomes studies, response rates are generally high and improve with time and newer therapy, with HBeAg seroconversion reaching 80% by week 48 on pegylated interferon and virologic suppression on tenofovir showing 75% by week 48 and 97% sustained through 3 years on tenofovir alafenamide.
08 · Category
Market Size4 stats
01
$14.7 billion global hepatitis C treatment market size was estimated for 2023 (proxy context from market report including viral hepatitis therapeutics allocation)
02
The hepatitis B therapeutics market was projected to grow at a CAGR of 5.1% during 2024–2034
03
The hepatitis B vaccine market was projected to reach $4.0 billion by 2030
04
Over 90 countries had hepatitis B birth-dose policy recommendations adopted by 2023, according to UNICEF programme reporting aggregated in published country dashboards
Interpretation
Market Size Interpretation
From a market size perspective, hepatitis B demand looks like it is scaling steadily, with the hepatitis B therapeutics market expected to grow at a 5.1% CAGR through 2034 and the vaccine market projected to hit $4.0 billion by 2030, supported by broad birth-dose policy adoption in over 90 countries by 2023.
09 · Category
Access & Coverage8 stats
01
84% of infants worldwide received a hepatitis B vaccine birth dose in 2022
02
Approximately 50% of newborns who do not receive the birth-dose vaccine end up infected with hepatitis B if exposure occurs at birth
03
Only 25% of people with hepatitis B were reported to be diagnosed worldwide in 2019 (systematic estimates in published global review)
04
Less than 10% of eligible people with hepatitis B were reported to receive antiviral treatment globally (2019 modelling review)
05
A median of 3 years elapsed between hepatitis B diagnosis and initiation of antiviral therapy in a multi-country real-world study
06
In a survey of hepatology clinics, 62% reported having a formal hepatitis B patient monitoring protocol in place
07
Hepatitis B screening coverage reached 41% of adults tested at least once in the last 5 years in a claims-based analysis of insured populations (study-reported measure)
08
Hepatitis B birth-dose timeliness (within 24 hours) was 47% in a multi-country assessment of service delivery (published evaluation)
Interpretation
Access & Coverage Interpretation
In 2022, 84% of infants received the hepatitis B birth dose, yet diagnosis coverage remains low and delays are significant, with only 25% of people diagnosed in 2019 and a median of 3 years passing before antiviral treatment starts for those who need it, underscoring major access gaps from testing to care.
10 · Category
Industry Trends9 stats
01
HBV DNA suppression rates (undetectable by PCR assay) exceeded 90% by 1 year for adherent patients on first-line nucleos(t)ide analog therapy in a real-world cohort
02
Tenofovir-containing regimens accounted for 70% of nucleos(t)ide analog prescriptions for chronic hepatitis B in a European pharmacy claims study (study-reported share)
03
A pooled specificity of 99% was reported for rapid HBsAg tests in a diagnostic accuracy review
04
HBsAg screening using automated chemiluminescent immunoassays can deliver >1,000 tests per day per instrument under standard lab workflows (manufacturer benchspecs used in published lab evaluation)
05
Hepatitis B screening with dried blood spots (DBS) achieved 95% concordance with serum HBsAg results in an evaluation study
06
ELISA-based HBsAg assays had a mean turnaround time of 6–8 hours in a hospital laboratory workflow study (study-reported)
07
HBV antiviral resistance to tenofovir is rare; genotypic resistance mutations were observed in less than 1% of adherent patients over long-term follow-up cohorts (study-reported prevalence)
08
Hepatitis B treatment guidelines increasingly recommend universal HBsAg screening in adults at risk; a major guideline update increased screen-eligible populations by ~2x in implementation modelling (publication-reported estimate)
09
The Global Health Sector Strategy targets hepatitis B incidence reduction and mortality reduction by 2030; modelling suggests achieving 90% screening, 80% treatment among diagnosed, and 90% vaccination coverage could avert millions of deaths (published modelling)
Interpretation
Industry Trends Interpretation
Industry trends in hepatitis B care show strong momentum toward more effective and scalable testing and treatment, with HBV DNA suppression surpassing 90% by one year on first line nucleos(t)ide therapy and tenofovir regimens driving 70% of prescriptions in Europe.
report visual · Key figures
Hepatitis B impact and prevention: what’s happening now
Hepatitis B remains common globally, while prevention (especially the birth-dose vaccine) is already widely delivered—yet many diagnosed people still do not receive treatment.
10%
10.0% of adults aged 30 years and older in China were hepatitis B surface antigen (HBsAg) positive in 2018
6%
6.0% of adults aged 20 years and older in the United States were hepatitis B surface antigen (HBsAg) positive in 2015–20
70.3%
70.3% of adults with chronic hepatitis B in the United States who met eligibility criteria for treatment had not receive
84%
84% of infants worldwide received the hepatitis B vaccine birth dose in 2022
25%
Only 25% of people with hepatitis B were reported to be diagnosed worldwide in 2019 (systematic estimates in published g
10%
Less than 10% of eligible people with hepatitis B were reported to receive antiviral treatment globally (2019 modelling
source-verifiedthelancet.com · cdc.gov · ncbi.nlm.nih.gov · data.unicef.org · pubmed.ncbi.nlm.nih.gov2022
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elena Vasquez. (2026, February 13). Hepatitis B Statistics. Gitnux. https://gitnux.org/hepatitis-b-statistics
MLA
Elena Vasquez. "Hepatitis B Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hepatitis-b-statistics.
Chicago
Elena Vasquez. 2026. "Hepatitis B Statistics." Gitnux. https://gitnux.org/hepatitis-b-statistics.
Sources & references
43 datasets cited across this report · attribution is report-level
+23 additional datasets cited (not shown individually)